Trial Profile
Randomized Phase II Study: Temozolomide (TMZ) Concomitant to Radiotherapy Followed by Sequential TMZ in Advanced Non-Small Cell Lung Cancer (NSCLC) Patients With Central Nervous System (CNS) Metastasis Versus Radiotherapy Alone.
Status:
Discontinued
Phase of Trial:
Phase II
Latest Information Update: 06 May 2022
Price :
$35
*
At a glance
- Drugs Temozolomide (Primary)
- Indications Cancer metastases; Non-small cell lung cancer
- Focus Therapeutic Use
- Sponsors Merck Sharp & Dohme; Schering-Plough
- 20 Mar 2008 The expected completion date for this trial is now 1 Aug 2009, as reported by clinicaltrials.gov
- 18 Sep 2006 New trial record.